Amphastar Pharmaceuticals EPS - Earnings per Share 2012-2024 | AMPH
Amphastar Pharmaceuticals eps - earnings per share from 2012 to 2024. Eps - earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.
| Amphastar Pharmaceuticals Annual EPS |
| 2023 |
$2.60 |
| 2022 |
$1.74 |
| 2021 |
$1.25 |
| 2020 |
$0.03 |
| 2019 |
$0.98 |
| 2018 |
$-0.12 |
| 2017 |
$0.08 |
| 2016 |
$0.21 |
| 2015 |
$-0.06 |
| 2014 |
$-0.25 |
| 2013 |
$0.31 |
| 2012 |
$0.46 |
| 2011 |
$0.20 |
| 2009 |
$0.00 |
| Amphastar Pharmaceuticals Quarterly EPS |
| 2024-09-30 |
$0.78 |
| 2024-06-30 |
$0.73 |
| 2024-03-31 |
$0.81 |
| 2023-12-31 |
$0.70 |
| 2023-09-30 |
$0.91 |
| 2023-06-30 |
$0.49 |
| 2023-03-31 |
$0.50 |
| 2022-12-31 |
$0.64 |
| 2022-09-30 |
$0.30 |
| 2022-06-30 |
$0.33 |
| 2022-03-31 |
$0.47 |
| 2021-12-31 |
$0.40 |
| 2021-09-30 |
$0.59 |
| 2021-06-30 |
$0.16 |
| 2021-03-31 |
$0.10 |
| 2020-12-31 |
$-0.13 |
| 2020-09-30 |
$0.08 |
| 2020-06-30 |
$0.00 |
| 2020-03-31 |
$0.08 |
| 2019-12-31 |
$-0.03 |
| 2019-09-30 |
$0.03 |
| 2019-06-30 |
$0.96 |
| 2019-03-31 |
$0.02 |
| 2018-12-31 |
$0.04 |
| 2018-09-30 |
$0.05 |
| 2018-06-30 |
$-0.06 |
| 2018-03-31 |
$-0.15 |
| 2017-12-31 |
$0.02 |
| 2017-09-30 |
$0.00 |
| 2017-06-30 |
$0.04 |
| 2017-03-31 |
$0.02 |
| 2016-12-31 |
$-0.07 |
| 2016-09-30 |
$0.08 |
| 2016-06-30 |
$0.15 |
| 2016-03-31 |
$0.05 |
| 2015-12-31 |
$0.17 |
| 2015-09-30 |
$-0.07 |
| 2015-06-30 |
$-0.15 |
| 2015-03-31 |
$-0.01 |
| 2014-12-31 |
$-0.06 |
| 2014-09-30 |
$-0.12 |
| 2014-06-30 |
$-0.03 |
| 2014-03-31 |
$-0.04 |
| 2013-12-31 |
$0.05 |
| 2013-09-30 |
$0.00 |
| 2013-06-30 |
$0.20 |
| 2013-03-31 |
$0.06 |
| 2012-12-31 |
$0.11 |
| 2012-09-30 |
$0.08 |
| 2012-06-30 |
$0.13 |
| 2012-03-31 |
$0.14 |
| 2011-12-31 |
$0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$1.835B |
$0.644B |
|
Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses primarily on developing, manufacturing, marketing, and selling generic and proprietary injectable and inhalation products. The company products include Enoxaparin Sodium Injection; Amphadase; Cortrosyn for Injection; and prefilled disposable emergency syringes for crash cart use. Amphastar Pharmaceuticals, Inc. is headquartered in Rancho Cucamonga, California.
|
